Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.